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We have recently argued the case for empirical studies evaluat-
ing the selective withdrawal of antidepressants in patients with
advanced kidney disease [1]. This was in response to a large ret-
rospective analysis that found that haemodialysis patients who
initiated selective serotonin reuptake inhibitors (SSRIs) with
higher QT-prolonging potential (citalopram and escitalopram)
had a significantly increased risk of sudden cardiac death {ad-
justed hazard ratio [HR] 1.18 [95% confidence interval (CI) 1.05–
1.31]} compared with patients who initiated SSRIs with lower
QT-prolonging potential (fluoxetine, fluvoxamine, paroxetine
and sertraline) [2]. Furthermore, we highlighted three random-
ized placebo-controlled trials of SSRIs in individuals with kidney
disease [3–5] that failed to show evidence of efficacy but indi-
cated increased risks of adverse events. We concluded an exis-
tent possibility that in some kidney patients, antidepressants
may be doing more harm than good, therefore consideration of
withdrawing antidepressants in suitable patients may be appro-
priate. A recent review of the evidence base for antidepressants
in the general population reports minimal benefit to the average
patient with major depressive disorder and concludes
‘Antidepressants should not be used for adults with major de-
pressive disorder before valid evidence has shown that the po-
tential beneficial effects outweigh the harmful effects’ [6].
Evidence regarding the association between depression
symptoms and survival in dialysis patients is unequivocal [7–9].
However, what is less clear is the role antidepressants have on
survival and whether any effect is independent of depression
severity. Assimon et al.’s [2] analysis, while compelling, does not
provide the mortality risk of being on an antidepressant versus
not. We therefore went back to reanalyse survival data pub-
lished previously [7] in order to explore the association between
antidepressant use and survival from a large sample of haemo-
dialysis patients (n¼ 707) in which there were 148 deaths. Our
original analyses demonstrated that depression severity pre-
dicted all-cause mortality after controlling for a variety of cova-
riates [Beck Depression Inventory-II, HR 1.03 (95% CI 1.01–1.04);
Patient Health Questionnaire-9 (PHQ-9), HR 1.04 (95% CI 1.01–
1.06)]. Using the same analytical methodology and model
adjustments, we reran the analyses including antidepressant
use within 3 months prior to the study assessment. Seventy-six
patients reported being on at least one antidepressant (six miss-
ing cases). Of those on antidepressants, 36% died during the
study follow-up compared with 19% of patients not on an anti-
depressant. In adjusted analysis that also controlled for depres-
sion severity (PHQ-9), antidepressant use was significantly
associated with mortality, increasing the hazard of death 2-fold
[adjusted HR 2.0 (95% CI 1.28–3.26); P¼ 0.003; see Figure 1 for sur-
vival plot]. Our previously reported findings from the original
analysis remained the same, including the significance and ef-
fect size of depression severity on mortality. This suggests that
the association between antidepressant use and mortality in
haemodialysis patients may well be independent of concurrent
depression severity. The estimated absolute risk increase of
death for those on an antidepressant was 18%, with a numbers
needed to harm of 5.
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This exploratory reanalysis is limited by patient self-
reported antidepressant use. We did not have data on medica-
tion type or regimen, dose or treatment vintage. Accordingly,
more robust studies are needed to ascertain more reliable esti-
mates from which to establish the absolute mortality risk in-
crease of antidepressants in this setting. Nevertheless, we feel it
is important to report this exploratory observation, which in our
opinion further supports the call for empirical studies investi-
gating the selective withdrawal of antidepressants in patients
with advanced kidney disease.
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P = 0.003
FIGURE 1: Adjusted survival plot comparing patients using an antidepressant in the previous 3 months prior to study assessment versus nouse.
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